Updates

First to the future of cardiac PET

06
Sep

POSITRON ANNOUNCES SALE OF ATTRIUS PET SCANNER

 

Niagara Falls, NY –September 5, 2018 – Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, is pleased to announce the sale of its Attrius PET scanner to a prominent cardiology practice in the US as they expand their services to include cardiac PET imaging

 

Positron’s President, Adel Abdullah stated, “its sale is significant as representation of the growing demand for cardiac PET and further proof of the value proposition Positron offers in meeting such demand”.

 

“We see demand for PET imaging continuing to accelerate further increasing the need for radiopharmaceuticals and imaging technology.  We believe that Positron’s Attrius PET scanner, clinical services and ability to provide innovative business structures is a perfect solution for all groups seeking to add cardiac PET to their practice”.

 

“Positron as a company offers the only dedicated PET system optimized of cardiac imaging with operations that are very efficient and effective to best serve our customers.  We are able to customize the financial structure, installation, training and continued services to meet the needs of our customers. I am pleased to add that with this customer we delivered ahead of schedule with only 30 days lead time. These are exciting times with much more to follow”.         

 

About Positron: Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron's unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron.  Positron is redefining the industry. 

More information about Positron is available at (317) 576-0183 or www.positron.com.

Forward Looking Statements:  Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

 

Print this page